Analytes
- 12 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) and 66, 68
Internal control (IC)
Specimens
- Liquid-based cytology(e.g., ThinPrep® and Surepath™)
- Cervical specimen
- Self-collected vaginal
- Liquid-based cytology
Human Papillomavirus Infections
HPV HR Detection
Anyplex™ II HPV HR Detection is a high multiplex real-time PCR product that provides genotypingand semi-quantitative information for each high-risk HPV type. It is suitable for more effective screening in termsof preventing and managing cervical cancer. Also, it provides convenience to users through a streamlinedautomation system. The application of endogenous internal control that can confirm the entire testing processfrom sample collection to result analysis helps provide highly reliable and reproducible results.
Provide semi-quantitative information
Fully automated workflow
Application of Seegene STARlet-AIOS™ providing one streamlined workflow from nucleic acids extraction to result analysis
Self-collected samples
Increased accessibility of HPV screening due to alternative sample collection method, enabling early prevention of cervical cancer
12 high-risk HPV and 66, 68 genotypes
Detecting and identifying 14 individual HPVs simultaneously with a single test
Monitoring of clearance and persistence of HPV genotypes and the risk of cervical cancer
Internal control (IC)
Real-time PCR
Automated Extraction
Automated Extraction & PCR Setup
Anyplex™ II HPV HR Detection
2025
Comparative performance of cobas 4800 HPV Test and Anyplex II HPV HR for high-risk human papillomavirus detection
Journal of Clinical Microbiology
2025
Molecular Detection of Human Papillomavirus (HPV) and Other Sexually Transmitted Pathogens in Cervical and Self-Collected Specimens
International Journal of Molecular Sciences
2025
Reflections Regarding Validation of New HPV Tests With Reduced HPV Genotypes: Report From an IARC Expert Consultation
Journal of Medical Virology
2024
Allplex HPV HR Detection assay fulfils all clinical performance and reproducibility validation requirements for primary cervical cancer screening
Journal of Clinical Virology
2024
High rate of non‑vaccine targeted high‑risk HPV genotypes circulate among women in Eastern Ethiopia
Scientific Reports